PMID- 35830001
OWN - NLM
STAT- MEDLINE
DCOM- 20220826
LR  - 20220826
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 82
IP  - 11
DP  - 2022 Jul
TI  - Tirzepatide: First Approval.
PG  - 1213-1220
LID - 10.1007/s40265-022-01746-8 [doi]
AB  - Tirzepatide (Mounjaro) is a single molecule that combines dual agonism of 
      glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 
      (GLP-1) receptors. Native GIP and GLP-1 are incretin hormones that stimulate 
      insulin secretion and decrease glucagon secretion. GIP also plays a role in 
      nutrient and energy metabolism, while GLP-1 also delays gastric emptying, 
      supresses appetite and improves satiety. Eli Lilly is developing tirzepatide for 
      the treatment of type 2 diabetes mellitus (T2DM), obesity, cardiovascular 
      disorders in T2DM, heart failure, non-alcoholic steatohepatitis, obstructive 
      sleep apnoea and for reducing mortality/morbidity in obesity. In May 2022, 
      tirzepatide received its first approval in the USA to improve glycaemic control 
      in adults with T2DM, as an adjunct to diet and exercise. Tirzepatide is in phase 
      III development for heart failure, obesity and cardiovascular disorders in T2DM, 
      and in phase II development for non-alcoholic steatohepatitis. This article 
      summarizes the milestones in the development of tirzepatide leading to this first 
      approval for T2DM.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Syed, Yahiya Y
AU  - Syed YY
AD  - Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. 
      dru@adis.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - OYN3CCI6QE (tirzepatide)
SB  - IM
MH  - Adult
MH  - *Diabetes Mellitus, Type 2/drug therapy/metabolism
MH  - *Fatty Liver
MH  - Gastric Inhibitory Polypeptide
MH  - Glucagon-Like Peptide 1
MH  - Glucagon-Like Peptide-1 Receptor
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - Obesity/drug therapy/metabolism
EDAT- 2022/07/14 06:00
MHDA- 2022/08/27 06:00
CRDT- 2022/07/13 11:25
PHST- 2022/07/14 06:00 [pubmed]
PHST- 2022/08/27 06:00 [medline]
PHST- 2022/07/13 11:25 [entrez]
AID - 10.1007/s40265-022-01746-8 [pii]
AID - 10.1007/s40265-022-01746-8 [doi]
PST - ppublish
SO  - Drugs. 2022 Jul;82(11):1213-1220. doi: 10.1007/s40265-022-01746-8.